Gordian Surgical announced that it has surpassed 2,000 surgeries globally with its FDA-cleared and CE-marked TroClose1200 access-and-closure system for laparoscopic surgery.
Until recently, surgeons had to either manually insert sutures in a time-consuming and sometimes difficult process at the conclusion of a lap surgical procedure, or close the lap port-site opening with an additional device. Improper lap port closure may result in an incidence of hernia up to 6 percent, where the intestine protrudes from a weakened abdominal muscle, necessitating additional surgery. Now, using the TroClose1200’s design, sutures are inserted into the tissue at the beginning of the procedure and anchored to remain in place throughout the operation, allowing port site incisions to be closed easily and quickly as designed upon removal of the TroClose1200 system.
“TroClose is a simple, effective device to close laparoscopic incisions. No longer do I have to point a sharp instrument toward the intestine or major blood vessels in the abdomen to close a 10-millimeter port. Besides saving time in the OR, TroClose will reduce inadvertent injury,” said Barry Salky, MD, Professor Emeritus of Surgery and Founder of the Division of Laparoscopic Surgery at Mount Sinai Hospital, New York, New York.
“This is a very exciting time for Gordian Surgical,” said Zvi Pe’er, CEO of Gordian Surgical. “We are an advanced-stage medical device company with not only outstanding clinical data from more than 2,000 surgeries, but also FDA/CE regulatory certifications and significant investments from B. Braun and other investment groups. We are ramping sales with a patented product that meets a critically important clinical need: improved safety in lap surgery.”